February 22, 2022 – Oxford, UK – The British Pharmacological Society (BPS), the membership charity with a mission to promote and advance all disciplines of pharmacology in the discovery, development and use of medicines, and global research and education leader Wiley, today announced their renewed publishing partnership. Wiley will continue to publish BPS’s leading journals, the British Journal of Pharmacology (BJP) and the British Journal of Clinical Pharmacology (BJCP), from 2023 to 2029.
BPS CEO, Rachel Lambert-Forsyth, commented “Pharmacology makes a unique contribution to research to develop new drugs and improving the use of existing drugs for better patient outcomes. Our journals disseminate this world-class research in pharmacology and provide opportunities for our members to come together so they can collaborate, debate, publish and ultimately make advances in priority research areas. Wiley supports us in this mission with their expertise in education and research and we are delighted to be continuing our partnership.”
First published in 1946, the British Journal of Pharmacology is the leading international general pharmacology journal, publishing high-quality original research and authoritative reviews on all aspects of experimental pharmacology. BJP is committed to leading the field in Open Research, transparency and scientific rigour, and hosts the highly regarded Concise Guide to Pharmacology. The journal celebrated its 75th anniversary in 2021.
First published in 1974, the British Journal of Clinical Pharmacology is a leading international clinical pharmacology journal that bridges the gap between the medical profession, clinical research and the pharmaceutical industry by addressing all aspects of drug action in humans.
“As the world’s largest society publisher, we are thrilled to continue our more than 25-year partnership with the British Pharmacological Society”, said Liz Ferguson, SVP, Research Publishing at Wiley. “Together, we are driving forward the BPS portfolio, focussing collectively on issues of current importance (such as diversity and inclusion, and research reproducibility and transparency), while developing new technological features to make the publishing experience even faster and more efficient for researchers advancing drug discovery.”
Under this renewed partnership between BPS and Wiley, BJP and BJCP will continue to focus on accelerating their transition to open access and on maintaining their excellent reputation for high-quality and timely research in the field of pharmacology.
About the British Pharmacological Society
With more than 4,500 members from 60+ countries worldwide, the British Pharmacological Society (BPS) is a collaborative, global community at the heart of pharmacology. It was founded in 1931 and now leads the way in the research and application of pharmacology around the world. Guided by the mission to promote and advance all disciplines of pharmacology in the discovery, development and use of medicines, the Society’s vision is a world in which pharmacology and therapeutics drive and support progress in science, medicine and healthcare, for the benefit of all in Society. Besides the British Journal of Pharmacology and the British Journal of Clinical Pharmacology, BPS publishes Pharmacology Matters, the society’s digital magazine and, in partnership with Wiley and the American Society for Pharmacology and Experimental Therapeutics (ASPET), Pharmacology Research & Perspectives, a peer-reviewed open-access journal.
Wiley (NYSE: JWA) is a global leader in research and education, unlocking human potential by enabling discovery, powering education, and shaping workforces. For over 200 years, Wiley has fuelled the world’s knowledge ecosystem. Today, our high-impact content, platforms, and services help researchers, learners, institutions, and corporations achieve their goals in an ever-changing world. Visit us at Wiley.com, Like us on Facebook, and follow us on Twitter and LinkedIn.
Dawn Peters, Wiley
Billy Nichols, BPS